|Articles|April 15, 2002

Potential treatment: Miravant regains rights to wet AMD therapy

Santa Barbara, CA-Miravant Medical Technologies plans to seek new applications for its primary drug candidate, a potential therapy for wet age-related macular degeneration (AMD)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME